Industry Adoption of Organoids and Organs‐on‐Chip Technology: Toward a Paradox of Choice
Source abstract
Abstract
Abstract During the last decade, organoid and organs‐on‐chip technologies have significantly enhanced the ability to model human biology in vitro. For the pharmaceutical industry, this represents an opportunity to augment, or possibly replace, traditional preclinical animal studies with more clinically predictive tools. In the last few years, the marketplace for new human model systems has expanded rapidly. While pharma companies welcome the breadth of new options, ample choice can be paralyzing. Even for experts from the model developer community who are now filling the ranks in the industry, the pairing of the right model for a specific, fit‐for‐purpose biological question can be daunting. As a community, the adoption of these models can be hastened in the industry by publishing high dimensional datasets (e.g., multiomic, imaging, functional, etc.) on existing model systems, termed model‐omics, and storing them in publicly accessible databases. This action will allow for quick cross‐model comparisons and provide a sought‐after rationale for either routine or fit‐for‐purpose use of organoids or organs‐on‐chip during drug development.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Single-cell and spatial transcriptomics · Gene Regulatory Network Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Director of the Complex In Vitro Systems (CiS) Group in Development Sciences Genentech, Inc. 1 DNA Way South San Francisco CA 94080 USA
References (30)
Show source-provided references
1. 10.1038/s41576-022-00466-910.1038/s41576-022-00466-9 ↗
2. 10.3389/fgene.2021.76762110.3389/fgene.2021.767621 ↗
3. 10.1016/j.yrtph.2020.10466210.1016/j.yrtph.2020.104662 ↗
4. Homan K. A. · Stem Cells Int. · 2016 · 6
5. 10.1039/D0LC01186J10.1039/D0LC01186J ↗
6. 10.1126/science.118830210.1126/science.1188302 ↗
7. 10.1016/j.tcb.2022.01.00310.1016/j.tcb.2022.01.003 ↗
8. 10.1039/C9LC01168D10.1039/C9LC01168D ↗
9. 10.1016/j.stemcr.2021.06.01510.1016/j.stemcr.2021.06.015 ↗
10. FDA Modernization Act 2.0 https://www.congress.gov/bill/117th-congress/senate-bill/5002(accessed: February2023).
11. 10.1039/C9LC00768G10.1039/C9LC00768G ↗
12. Aceves J. O. · Stem Cells Int. · 2022 · 12
13. 10.1124/mol.117.11115310.1124/mol.117.111153 ↗
14. 10.1016/j.xphs.2021.01.02810.1016/j.xphs.2021.01.028 ↗
15. 10.1039/D1LC00241D10.1039/D1LC00241D ↗
16. 10.1042/BST2021084010.1042/BST20210840 ↗
17. U.Marx Biology‐inspired microphysiological systems to advance medicines for patient benefit and animal welfare ALTEX https://doi.org/10.14573/altex.2001241(accessed:2020).
18. 10.1016/j.tiv.2020.10492810.1016/j.tiv.2020.104928 ↗
19. 10.1093/toxsci/kfy26810.1093/toxsci/kfy268 ↗
20. 10.1038/s43856-022-00209-110.1038/s43856-022-00209-1 ↗
21. 10.1093/nar/gkaa110510.1093/nar/gkaa1105 ↗
22. 10.7554/eLife.2704110.7554/eLife.27041 ↗
23. 10.1038/ng1007-118110.1038/ng1007-1181 ↗
24. 10.3390/genes812036810.3390/genes8120368 ↗
25. Zhang Y. · Nucleic Acids Res. · 2021 · 50
26. 10.1093/database/baz04610.1093/database/baz046 ↗
27. 10.1089/aivt.2016.001110.1089/aivt.2016.0011 ↗
28. Ma Q. · Nucleic Acids Res. · 2022 · 51
29. 10.1007/978-1-4939-3578-9_510.1007/978-1-4939-3578-9_5 ↗
30. 10.1093/database/baaa07310.1093/database/baaa073 ↗